Browse Topic
Stem Cells
-
January 31, 2024What you need to know about spina bifida and spinal cord injuries
In a Q&A, UC Davis Health physical medicine and rehabilitation specialist Maya Evans shares how clinicians and parents can provide comprehensive care for children with spinal cord injuries and spina bifida.
Read More -
January 29, 2024UC Davis Health leads study on promising stem cell-based therapy for Crohn’s disease
A stem cell therapy for Crohn's disease developed by gastroenterology researchers has shown promising results in mouse studies.
Read More
-
December 19, 2023New bioengineered scaffold may help large deep burn wounds heal faster
Professor Aijun Wang has designed and tested a structure that can help large deep burn wounds heal faster and potentially reduce the need for skin autografting.
Read More
-
November 29, 2023State stem cell agency, Shriners Children’s award $15 million to UC Davis CuRe trial
Fetal surgeon Diana Farmer and bioengineer Aijun Wang have been awarded $15 million by the state’s stem cell agency and Shriners Children’s to test their stem cell treatment for spina bifida.
Read More
-
October 25, 2023Meet the UC Davis Good Manufacturing Practice Facility’s new homegrown leader
A Q&A with the new director of UC Davis Good Manufacturing Practice (GMP) facility Brian Fury to learn about the GMP’s plans and recent California Institute for Regenerative Medicine (CIRM) $1.7 million award.
Read More
-
September 13, 2023Record external funding supports UC Davis School of Medicine research
UC Davis exceeded $1 billion in external research funding in the fiscal year 2022–23. The School of Medicine contributed 40% of this amount, achieving a new research funding record.
Read More
-
June 07, 2023UC Davis and Orgenesis partner to boost access to gene and cell therapies in California
UC Davis and Orgenesis are rolling out processing units that allow cell and gene therapies to be developed and manufactured onsite. This will increase patient access to therapies.
Read More
-
April 18, 2023
UC Davis Health receives 2023 Top Ten Clinical Research Achievement Award
Chair of Physical Medicine and Rehabilitation Craig McDonald was honored with a 2023 Top Ten Clinical Research Achievement Award, in recognition of his remarkable work on Duchenne muscular dystrophy.
Read More
-
February 28, 2023Clinical trial for patients with swallowing difficulties after cancer treatment
Researchers have begun a new stem cell clinical trial to treat patients with swallowing problems. The study takes stem cells and injects them into the patient’s tongue.
Read More -
February 21, 2023UC Davis Health to develop in-utero therapy for Duchenne muscular dystrophy
Professor Aijun Wang won a $2 million grant from California’s Stem Cell Agency to develop a cure to Duchenne muscular dystrophy (DMD) using an in-utero gene editing formula.
Read More
-
December 27, 2022UC Davis partners with Caring Cross and CIRM to develop immunotherapy for cancer patients
Immunologist William Murphy discusses CAR T-cell cancer therapy and his work with Caring Cross, CIRM and UC Davis researchers to find novel cures to leukemia and lymphoma.
Read More -
December 14, 2022UC Davis Alpha Stem Cell Clinic receives $8 million from California’s stem cell agency
CIRM awarded UC Davis’ Alpha Stem Cell Clinic an $8 million grant renewal to expand its successful clinical trials operation and advance toward onsite manufacturing of therapies.
Read More
-
October 11, 2022CuRe trial gives hope to new mom
Michelle and Jeff were excited to build their new family together, but when she received the distressing news that her developing baby was diagnosed with spina bifida, she looked for the best treatment. She was referred to the CuRe trial.
Read More -
October 06, 2022
World’s first stem cell treatment for spina bifida delivered during fetal surgery
Three babies have been born after receiving the world’s first spina bifida treatment combining surgery with stem cells. This was made possible by a landmark clinical trial at UC Davis Health known formally as the “CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele.”
Read More
-
August 22, 2022Surgery resident awarded prestigious T32 federal research grant
Cardiothoracic surgery resident Nataliya Bahatyrevich has become the latest UC Davis trainee to receive a prestigious T32 federal research grant. The award will allow her to spend a year in the laboratory and pursue a Master of Science in biomedical engineering at UC Davis
Read More
-
June 17, 2022Jan Nolta receives 2022 Chancellor’s Lifetime Achievement Award in Innovation
Stem cell researcher Jan Nolta received the Lifetime Achievement Award in Innovation during the 2022 Chancellor’s Innovation Awards ceremony on June 16. The awards recognize faculty, community partners and industry leaders developing innovative solutions to improve the lives of others and address important needs in the global society.
Read More
-
May 26, 2022UC Davis wins $3 million CIRM grant to develop smart vascular graft for kidney patients
Professor Aijun Wang won $3 million grant from California Institute for Regenerative Medicine to develop a smart durable vascular device for hemodialysis patients treated for kidney failure. The device uses a unique molecule to help prevent synthetic vascular graft failure, a common problem for patients undergoing hemodialysis.
Read More
-
March 29, 2022$4 million research program seeks therapy for rare genetic condition ADNP syndrome
The UC Davis MIND Institute is launching a $4 million research program aimed at finding transformative therapies for ADNP syndrome, a rare genetic condition. A group of interdisciplinary researchers will evaluate multiple gene therapies for possible use.
Read More -
March 10, 2022Cellular therapy improves signs and symptoms of Duchenne muscular dystrophy
In a first of its kind clinical trial led by UC Davis Health, HOPE-2 showed that cellular therapy is safe and effective in stopping the deterioration of upper limb and heart functions in patients with late-stage Duchenne muscular dystrophy.
Read More
-
December 16, 2021New potential treatment for graft-versus-host-disease and other inflammatory disorders
UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease, an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation.
Read More